Reneuron Group Plc (RNUGF) 0.0400 $RNUGF
Retinitis Pigmentosa Pipeline Review, H2 2015 Featuring 27 Companies and Respective Drug Profiles
M2 - Fri Feb 05, 4:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/pz5gtq/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Retinitis Pigmentosa Overview - Therapeutics Development - Pipeline Products for Retinitis Pigmentosa - Overview - Pipeline Products for Retinitis Pigmentosa - Comparative Analysis - Retinitis Pigmentosa - Therapeutics under Development by Companies - Retinitis Pigmentosa - Therapeutics under Investigation by Universities/Institutes - Retinitis Pigmentosa - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Retinitis Pigmentosa - Products under Development by Companies - Retinitis Pigmentosa - Products under Investigation by Universities/Institutes - Retinitis Pigmentosa - Companies Involved in Therapeutics Development - Acucela Inc. - Amarantus Bioscience Holdings, Inc. - Applied Genetic Technologies Corporation - Asklepios BioPharmaceutical, Inc. - Caladrius Biosciences, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - Genable Technologies Limited - Genethon - GenSight Biologics SA - Grupo Ferrer Internacional, S.A. - InFlectis BioScience - International Stem Cell Corporation - Isis Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Neurotech Pharmaceuticals, Inc. - Ocata Therapeutics, Inc. - Orphagen Pharmaceuticals, Inc. - QLT Inc. - RegenxBio Inc. - ReNeuron Group Plc - SanBio, Inc. - Sanofi - Shire Plc - Spark Therapeutics, Inc. - Sucampo Pharmaceuticals, Inc. - Sun Pharma Advanced Research Company Ltd. For more information visit http://www.researchandmarkets.com/research/pz5gtq/retinitis
OCAT: 8.47 (+0.01), QLTI: 1.39 (-0.01), ISIS: 57.56 (-0.28), ONCE: 59.66 (+1.27), SHPG: 200.87 (+0.28), SCMP: 11.85 (+0.13), GNST: (), CLBS: 6.25 (-0.06)
Global Ischemia Therapeutic Development Pipeline Review, H2 2015
M2 - Mon Feb 01, 8:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/4b8tfd/ischemia) has announced the addition of the "Ischemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Ischemia Overview - Therapeutics Development - Pipeline Products for Ischemia - Overview - Pipeline Products for Ischemia - Comparative Analysis - Ischemia - Therapeutics under Development by Companies - Ischemia - Therapeutics under Investigation by Universities/Institutes - Ischemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Ischemia - Products under Development by Companies - Ischemia - Products under Investigation by Universities/Institutes - Ischemia - Companies Involved in Therapeutics Development - Alize Pharma SAS - Amyndas Pharmaceuticals LLC - AnGes MG, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Baxalta Incorporated - Caladrius Biosciences, Inc. - Cellmid Limited - CoDa Therapeutics, Inc. - CohBar, Inc. - Cynata Therapeutics Limited - DNAVEC Corporation - GlaxoSmithKline Plc - Hemostemix Ltd - IntelliCell BioSciences Inc. - Juventas Therapeutics, Inc. - Kasiak Research Private Limited - Lixte Biotechnology Holdings, Inc. - Mesoblast Limited - Miltenyi Biotec GmbH - Mirrx Therapeutics A/S - Multi Gene Vascular Systems Ltd - NoNO, Inc. - Nyken BV - Pathfinder Cell Therapy, Inc. - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - Protagenic Therapeutics Inc. - ReNeuron Group Plc - Sihuan Pharmaceutical Holdings Group Ltd. - Stempeutics Research Private Limited - Targazyme, Inc. - Taxus Cardium Pharmaceuticals Group Inc. - TikoMed AB - U.S. Stem Cell, Inc. For more information visit http://www.researchandmarkets.com/research/4b8tfd/ischemia
PSTI: 1.51 (unch), GSK: 44.89 (-0.19), CLBS: 6.25 (-0.06), MESO: 4.31 (-0.02), ATHX: 2.14 (+0.05), BXLT: 46.02 (-0.18)
Critical Limb Ischemia - Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/htv6p6/critical_limb) has announced the addition of the "Critical Limb Ischemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Critical Limb Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Critical Limb Ischemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Critical Limb Ischemia Overview - Therapeutics Development - Pipeline Products for Critical Limb Ischemia - Overview - Pipeline Products for Critical Limb Ischemia - Comparative Analysis - Critical Limb Ischemia - Therapeutics under Development by Companies - Critical Limb Ischemia - Therapeutics under Investigation by Universities/Institutes - Critical Limb Ischemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Critical Limb Ischemia - Products under Development by Companies - Critical Limb Ischemia - Products under Investigation by Universities/Institutes - Critical Limb Ischemia - Companies Involved in Therapeutics Development - AnGes MG, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Caladrius Biosciences, Inc. - Cynata Therapeutics Limited - DNAVEC Corporation - Hemostemix Ltd - IntelliCell BioSciences Inc. - Juventas Therapeutics, Inc. - Kasiak Research Private Limited - Multi Gene Vascular Systems Ltd - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - ReNeuron Group Plc - Stempeutics Research Private Limited - Targazyme, Inc. - TikoMed AB - U.S. Stem Cell, Inc. - Vericel Corporation - ViroMed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/ht...tical_limb
VCEL: 2.35 (+0.07), PSTI: 1.51 (unch), ATHX: 2.14 (+0.05), CLBS: 6.25 (-0.06)
Global Stem Cell Banking Market 2015-2019 with Esperite, NeoStem, Smart Cells International, StemCyte & ViaCord Dominating
M2 - Wed Oct 28, 5:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/48756j/global_stem_cell) has announced the addition of the "Global Stem Cell Banking Market 2015-2019" report to their offering. The global stem cell banking market to grow at a CAGR of 15.13% over the period 2014-2019. The report, Global Stem Cell Banking Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. The global stem cell banking market shows some growth potential because of the emergence of certain trends. One such trend is the growing awareness among the public. The adoption of this concept is growing faster in larger cities and with the upper classes who have higher disposable incomes. Stem cell transplantation services are increasing as it is necessary to create awareness among the population for the optimum utilization of these facilities. According to the report, several factors are driving the global stem cell banking market. One such factor is the rising potential for umbilical cord cell banks. Umbilical cord blood is the blood that remains in the attached umbilical cord after childbirth. This blood is a rich source of stem cells that can be used for transplants because of their ability to regenerate. Further, the report states that one of the major challenges confronting the global stem cell banking market is the huge operational costs associated with the processing and storage of stem cells. These high costs are a major challenge that is leading to a dip in the growth of the market. The report also considers the revenue generated by various segments of stem cell banks to arrive at the final market size which includes: - Applications - Products - Geography Key vendors - Esperite - NeoStem - Smart Cells International - StemCyte - ViaCord Other prominent vendors - Aldagen - Arteriocyte - Brainstorm Cell Therapeutics - Capricor - Cellartis - Cellerant Therapeutics - Cellular Dynamics International - CordCare - Cryo Stemcell - Cryo-Save India - Cytori Therapeutics - Gamida Cell - GlobalStem - International Stem Cell - Jeevan Blood Bank Research Center - Medistem - NovaCord - Reelabs - ReNeuron Group - RhinoCyte - RMS Regrow - Stemade Biotech - StemCells - StemCyte India Therapeutics - StemOne Biologicals Key Topics Covered: Part 01: Executive summary Part 02: Scope of the report Part 03: Market research methodology Part 04: Introduction Part 05: Market landscape Part 06: Market segmentation by application Part 07: Market segmentation by products Part 08: Geographical segmentation Part 09: Market drivers Part 10: Impact of drivers Part 11: Market challenges Part 12: Impact of drivers and challenges Part 13: Market trends Part 14: Vendor landscape Part 15: Key vendor analysis Part 16: Appendix For more information visit http://www.researchandmarkets.com/research/48..._stem_cell
ICEL: 16.55 (+0.03), CYTX: 2.04 (-0.14), BCLI: 2.45 (+0.04)
Retinitis Pigmentosa (Retinitis) Therapeutics Pipeline Review, H1 2015 - 24 Companies & 42 Drug Profiles
M2 - Tue Jul 28, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p6vhmx/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa (Retinitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa (Retinitis) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acucela Inc. - Amarantus Bioscience Holdings, Inc. - Applied Genetic Technologies Corporation - Asklepios BioPharmaceutical, Inc. - BioDiem Ltd - Caladrius Biosciences, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - Genable Technologies Limited - GenSight Biologics SA - Grupo Ferrer Internacional, S.A. - International Stem Cell Corporation - Isis Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Neurotech Pharmaceuticals, Inc. - Ocata Therapeutics, Inc. - Orphagen Pharmaceuticals, Inc. - QLT Inc. - R-Tech Ueno, Ltd. - ReNeuron Group Plc - Sanofi - Shire Plc - Spark Therapeutics, Inc. - Sun Pharma Advanced Research Company Ltd. Drug Profiles - AMRS-001 - Antibodies to Antagonize IL-6 for Retinitis - BDM-E - BNP-RP - CB-11 - ECL-1 - emixustat hydrochloride - FIB-111 - Gene Therapy for Glaucoma and Retinitis Pigmentosa - Gene Therapy for Ocular Diseases - Gene Therapy for Ophthalmology - Gene Therapy for Retinitis Pigmentosa - Gene Therapy to Activate HDAC4 for Retinitis Pigmentosa - Gene Therapy to Activate RPGR for X-Linked Retinitis Pigmentosa - GS-020 - GT-038 - ISISRHO-2.5Rx - KIRA-6 - NT-501 - OCU-100 - PRO-015 - proinsulin human SR - QLT-091001 - Recombinant Human Nerve Growth Factor - ReN-003 - Retinal Progenitor Cells for Ophthalmological Disorders - RGX-321 - RST-001 - SAR-421869 - SHP-630 - Small Molecule for Retinitis Pigmentosa - Small Molecule to Agonize Neurotrophin Receptor for Retinitis Pigmentosa - Small Molecules for CNS Disorders and Ophthalmology - Small Molecules for Retinitis Pigmentosa - Small Molecules for Retinitis Pigmentosa For more information visit http://www.researchandmarkets.com/research/p6vhmx/retinitis
OCAT: 8.47 (+0.01), QLTI: 1.39 (-0.01), ISIS: 57.56 (-0.28), ONCE: 59.66 (+1.27), SHPG: 200.87 (+0.28), GNST: (), CLBS: 6.25 (-0.06)
Critical Limb Ischemia Therapeutics Pipeline Review, H1 2015 - 18 Companies & 28 Drug Profiles
M2 - Tue Jul 21, 4:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sc45jz/critical_limb) has announced the addition of the "Critical Limb Ischemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Critical Limb Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Critical Limb Ischemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AnGes MG, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Bioheart, Inc. - DNAVEC Corporation - Hemostemix Ltd - IntelliCell BioSciences Inc. - Juventas Therapeutics, Inc. - Kasiak Research Pvt. Ltd. - Multi Gene Vascular Systems Ltd - NeoStem, Inc. - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - ReNeuron Group plc - Stempeutics Research Private Limited - TikoMed AB - Vericel Corporation - ViroMed Co., Ltd. Drug Profiles - ACP-01 - AdipoCell - Alecmestencel-T - AMR-001 - ASCT-01 - Autologous Vascular Cells Therapy - beperminogene perplasmid - Cell Therapy for Critical Limb Ischemia - Cellgram for Severe Lower Limb Ischemia - DVC1-0101 - Gene Therapy for Critical Limb Ischemia and Peripheral Arterial Disease - Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Disease and Central Nervous System Disorders - ixmyelocel-T - JVS-100 - MultiGeneAngio - MultiStem - PLX-PAD - Protein for Myocardial Infarction and Critical Limb Ischemia - Recombinant Protein for Critical Limb Ischemia - Refacell-CLI - ReN-009 - Stem Cell Therapy for Critical Limb Ischemia - Stem Cell Therapy for Critical Limb Ischemia - Stem Cell Therapy to Activate VEGF for Critical Limb Ischemia - Stempeucel - Stromal Cell Therapy for Critical Limb Ischemia - TM-700 - VM-202 For more information visit http://www.researchandmarkets.com/research/sc...tical_limb
VCEL: 2.35 (+0.07), PSTI: 1.51 (unch), NBS: 2.25 (-0.09), ATHX: 2.14 (+0.05)
Leading 100 Global Fastest Growing Medical Devices/Technology/Supplies Companies 2015
M2 - Tue Mar 24, 7:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7ncq7z/global_fastest) has announced the addition of the "Global Fastest Growing Medical Devices/Technology/Supplies 100 - An Industry Report" report to their offering. The outlook for the medical device industry seems bright, with sales expected to still increase despite global economies struggling. The medical device market growth rate is expected to accelerate to 4.4% annually and reach $440 billion by 2018. This newly launched report identifies 100 Fastest Growing medical devices/technology/supplies companies globally and covers various aspects of these 100 companies including news, financial/non-financial information and stock market analysis. That is a growth rate almost 33% faster than the prescription drug market, which is expected to grow at a rate of 2.5% annually. The medical device market includes everything from large imaging systems to tongue depressors. While the pharmaceutical market represents a larger amount of dollars, the device market is responsible for more orders and transactions. The medical devices market is a major contributor to the overall healthcare industry with the pharmaceuticals industry leading the healthcare sector. The rising incidence of various diseases in the areas of Cardiovascular devices (CVD), respiratory, oncology, neurology, and many others have expanded the need for faster and better medical devices for treatment and diagnosis. The study of global top 100, by various attributes, in the medical devices market is important mainly due to continuous technological advancements in the medical devices industry and rising demand for medical devices owing to increasing healthcare issues. Report Highlights: - Global Fastest Growing 100 medical devices/technology/supplies companies - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of Global Fastest Growing medical devices/technology/supplies companies with foreign companies - International presence of Global Fastest Growing medical devices/technology/supplies companies - Key R&D activities by Global Fastest Growing medical devices/technology/supplies companies Companies Mentioned (Partial List) - Aethlon Medical Inc. (United States) - Anteo Diagnostics Limited (Australia) - Artventive Medical Group, Inc (United States) - Biodrain Medical Inc (United States) - Cardiovascular Systems, Incorporation (United States) - Electrical Geodesics, Inc. (United States) - GI Dynamics, Inc. (United States) - Inovio Pharmaceuticals Inc (United States) - Neurosynaptic Communications Pvt. Ltd (India) - Oncosil Medical Ltd (Australia) - ReNeuron Group plc (United Kingdom) - Rewalk Robotics Ltd (United States) - Scivision Biotech Inc (Taiwan) - SPO Global Inc (United States) - Suda Ltd (Australia) - West Pharmaceutical Packaging India Pvt Ltd (India) - Windmill Health Technologies Private Limited (India) - Xtremum Solutions Private Limited (India) For more information visit http://www.researchandmarkets.com/research/7n...al_fastest
INO: 9.85 (+0.21), CSII: 21.33 (+0.10), AEMD: 6.30 (-0.04)
Retinitis Pigmentosa Pipeline Review, H2 2015 Featuring 27 Companies and Respective Drug Profiles
M2 - Fri Feb 05, 4:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/pz5gtq/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Retinitis Pigmentosa Overview - Therapeutics Development - Pipeline Products for Retinitis Pigmentosa - Overview - Pipeline Products for Retinitis Pigmentosa - Comparative Analysis - Retinitis Pigmentosa - Therapeutics under Development by Companies - Retinitis Pigmentosa - Therapeutics under Investigation by Universities/Institutes - Retinitis Pigmentosa - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Retinitis Pigmentosa - Products under Development by Companies - Retinitis Pigmentosa - Products under Investigation by Universities/Institutes - Retinitis Pigmentosa - Companies Involved in Therapeutics Development - Acucela Inc. - Amarantus Bioscience Holdings, Inc. - Applied Genetic Technologies Corporation - Asklepios BioPharmaceutical, Inc. - Caladrius Biosciences, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - Genable Technologies Limited - Genethon - GenSight Biologics SA - Grupo Ferrer Internacional, S.A. - InFlectis BioScience - International Stem Cell Corporation - Isis Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Neurotech Pharmaceuticals, Inc. - Ocata Therapeutics, Inc. - Orphagen Pharmaceuticals, Inc. - QLT Inc. - RegenxBio Inc. - ReNeuron Group Plc - SanBio, Inc. - Sanofi - Shire Plc - Spark Therapeutics, Inc. - Sucampo Pharmaceuticals, Inc. - Sun Pharma Advanced Research Company Ltd. For more information visit http://www.researchandmarkets.com/research/pz5gtq/retinitis
OCAT: 8.47 (+0.01), QLTI: 1.39 (-0.01), ISIS: 57.56 (-0.28), ONCE: 59.66 (+1.27), SHPG: 200.87 (+0.28), SCMP: 11.85 (+0.13), GNST: (), CLBS: 6.25 (-0.06)
Global Ischemia Therapeutic Development Pipeline Review, H2 2015
M2 - Mon Feb 01, 8:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/4b8tfd/ischemia) has announced the addition of the "Ischemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Ischemia Overview - Therapeutics Development - Pipeline Products for Ischemia - Overview - Pipeline Products for Ischemia - Comparative Analysis - Ischemia - Therapeutics under Development by Companies - Ischemia - Therapeutics under Investigation by Universities/Institutes - Ischemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Ischemia - Products under Development by Companies - Ischemia - Products under Investigation by Universities/Institutes - Ischemia - Companies Involved in Therapeutics Development - Alize Pharma SAS - Amyndas Pharmaceuticals LLC - AnGes MG, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Baxalta Incorporated - Caladrius Biosciences, Inc. - Cellmid Limited - CoDa Therapeutics, Inc. - CohBar, Inc. - Cynata Therapeutics Limited - DNAVEC Corporation - GlaxoSmithKline Plc - Hemostemix Ltd - IntelliCell BioSciences Inc. - Juventas Therapeutics, Inc. - Kasiak Research Private Limited - Lixte Biotechnology Holdings, Inc. - Mesoblast Limited - Miltenyi Biotec GmbH - Mirrx Therapeutics A/S - Multi Gene Vascular Systems Ltd - NoNO, Inc. - Nyken BV - Pathfinder Cell Therapy, Inc. - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - Protagenic Therapeutics Inc. - ReNeuron Group Plc - Sihuan Pharmaceutical Holdings Group Ltd. - Stempeutics Research Private Limited - Targazyme, Inc. - Taxus Cardium Pharmaceuticals Group Inc. - TikoMed AB - U.S. Stem Cell, Inc. For more information visit http://www.researchandmarkets.com/research/4b8tfd/ischemia
PSTI: 1.51 (unch), GSK: 44.89 (-0.19), CLBS: 6.25 (-0.06), MESO: 4.31 (-0.02), ATHX: 2.14 (+0.05), BXLT: 46.02 (-0.18)
Critical Limb Ischemia - Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/htv6p6/critical_limb) has announced the addition of the "Critical Limb Ischemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Critical Limb Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Critical Limb Ischemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Critical Limb Ischemia Overview - Therapeutics Development - Pipeline Products for Critical Limb Ischemia - Overview - Pipeline Products for Critical Limb Ischemia - Comparative Analysis - Critical Limb Ischemia - Therapeutics under Development by Companies - Critical Limb Ischemia - Therapeutics under Investigation by Universities/Institutes - Critical Limb Ischemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Critical Limb Ischemia - Products under Development by Companies - Critical Limb Ischemia - Products under Investigation by Universities/Institutes - Critical Limb Ischemia - Companies Involved in Therapeutics Development - AnGes MG, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Caladrius Biosciences, Inc. - Cynata Therapeutics Limited - DNAVEC Corporation - Hemostemix Ltd - IntelliCell BioSciences Inc. - Juventas Therapeutics, Inc. - Kasiak Research Private Limited - Multi Gene Vascular Systems Ltd - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - ReNeuron Group Plc - Stempeutics Research Private Limited - Targazyme, Inc. - TikoMed AB - U.S. Stem Cell, Inc. - Vericel Corporation - ViroMed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/ht...tical_limb
VCEL: 2.35 (+0.07), PSTI: 1.51 (unch), ATHX: 2.14 (+0.05), CLBS: 6.25 (-0.06)
Global Stem Cell Banking Market 2015-2019 with Esperite, NeoStem, Smart Cells International, StemCyte & ViaCord Dominating
M2 - Wed Oct 28, 5:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/48756j/global_stem_cell) has announced the addition of the "Global Stem Cell Banking Market 2015-2019" report to their offering. The global stem cell banking market to grow at a CAGR of 15.13% over the period 2014-2019. The report, Global Stem Cell Banking Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. The global stem cell banking market shows some growth potential because of the emergence of certain trends. One such trend is the growing awareness among the public. The adoption of this concept is growing faster in larger cities and with the upper classes who have higher disposable incomes. Stem cell transplantation services are increasing as it is necessary to create awareness among the population for the optimum utilization of these facilities. According to the report, several factors are driving the global stem cell banking market. One such factor is the rising potential for umbilical cord cell banks. Umbilical cord blood is the blood that remains in the attached umbilical cord after childbirth. This blood is a rich source of stem cells that can be used for transplants because of their ability to regenerate. Further, the report states that one of the major challenges confronting the global stem cell banking market is the huge operational costs associated with the processing and storage of stem cells. These high costs are a major challenge that is leading to a dip in the growth of the market. The report also considers the revenue generated by various segments of stem cell banks to arrive at the final market size which includes: - Applications - Products - Geography Key vendors - Esperite - NeoStem - Smart Cells International - StemCyte - ViaCord Other prominent vendors - Aldagen - Arteriocyte - Brainstorm Cell Therapeutics - Capricor - Cellartis - Cellerant Therapeutics - Cellular Dynamics International - CordCare - Cryo Stemcell - Cryo-Save India - Cytori Therapeutics - Gamida Cell - GlobalStem - International Stem Cell - Jeevan Blood Bank Research Center - Medistem - NovaCord - Reelabs - ReNeuron Group - RhinoCyte - RMS Regrow - Stemade Biotech - StemCells - StemCyte India Therapeutics - StemOne Biologicals Key Topics Covered: Part 01: Executive summary Part 02: Scope of the report Part 03: Market research methodology Part 04: Introduction Part 05: Market landscape Part 06: Market segmentation by application Part 07: Market segmentation by products Part 08: Geographical segmentation Part 09: Market drivers Part 10: Impact of drivers Part 11: Market challenges Part 12: Impact of drivers and challenges Part 13: Market trends Part 14: Vendor landscape Part 15: Key vendor analysis Part 16: Appendix For more information visit http://www.researchandmarkets.com/research/48..._stem_cell
ICEL: 16.55 (+0.03), CYTX: 2.04 (-0.14), BCLI: 2.45 (+0.04)
Retinitis Pigmentosa (Retinitis) Therapeutics Pipeline Review, H1 2015 - 24 Companies & 42 Drug Profiles
M2 - Tue Jul 28, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p6vhmx/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa (Retinitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa (Retinitis) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acucela Inc. - Amarantus Bioscience Holdings, Inc. - Applied Genetic Technologies Corporation - Asklepios BioPharmaceutical, Inc. - BioDiem Ltd - Caladrius Biosciences, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - Genable Technologies Limited - GenSight Biologics SA - Grupo Ferrer Internacional, S.A. - International Stem Cell Corporation - Isis Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Neurotech Pharmaceuticals, Inc. - Ocata Therapeutics, Inc. - Orphagen Pharmaceuticals, Inc. - QLT Inc. - R-Tech Ueno, Ltd. - ReNeuron Group Plc - Sanofi - Shire Plc - Spark Therapeutics, Inc. - Sun Pharma Advanced Research Company Ltd. Drug Profiles - AMRS-001 - Antibodies to Antagonize IL-6 for Retinitis - BDM-E - BNP-RP - CB-11 - ECL-1 - emixustat hydrochloride - FIB-111 - Gene Therapy for Glaucoma and Retinitis Pigmentosa - Gene Therapy for Ocular Diseases - Gene Therapy for Ophthalmology - Gene Therapy for Retinitis Pigmentosa - Gene Therapy to Activate HDAC4 for Retinitis Pigmentosa - Gene Therapy to Activate RPGR for X-Linked Retinitis Pigmentosa - GS-020 - GT-038 - ISISRHO-2.5Rx - KIRA-6 - NT-501 - OCU-100 - PRO-015 - proinsulin human SR - QLT-091001 - Recombinant Human Nerve Growth Factor - ReN-003 - Retinal Progenitor Cells for Ophthalmological Disorders - RGX-321 - RST-001 - SAR-421869 - SHP-630 - Small Molecule for Retinitis Pigmentosa - Small Molecule to Agonize Neurotrophin Receptor for Retinitis Pigmentosa - Small Molecules for CNS Disorders and Ophthalmology - Small Molecules for Retinitis Pigmentosa - Small Molecules for Retinitis Pigmentosa For more information visit http://www.researchandmarkets.com/research/p6vhmx/retinitis
OCAT: 8.47 (+0.01), QLTI: 1.39 (-0.01), ISIS: 57.56 (-0.28), ONCE: 59.66 (+1.27), SHPG: 200.87 (+0.28), GNST: (), CLBS: 6.25 (-0.06)
Critical Limb Ischemia Therapeutics Pipeline Review, H1 2015 - 18 Companies & 28 Drug Profiles
M2 - Tue Jul 21, 4:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sc45jz/critical_limb) has announced the addition of the "Critical Limb Ischemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Critical Limb Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Critical Limb Ischemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AnGes MG, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Bioheart, Inc. - DNAVEC Corporation - Hemostemix Ltd - IntelliCell BioSciences Inc. - Juventas Therapeutics, Inc. - Kasiak Research Pvt. Ltd. - Multi Gene Vascular Systems Ltd - NeoStem, Inc. - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - ReNeuron Group plc - Stempeutics Research Private Limited - TikoMed AB - Vericel Corporation - ViroMed Co., Ltd. Drug Profiles - ACP-01 - AdipoCell - Alecmestencel-T - AMR-001 - ASCT-01 - Autologous Vascular Cells Therapy - beperminogene perplasmid - Cell Therapy for Critical Limb Ischemia - Cellgram for Severe Lower Limb Ischemia - DVC1-0101 - Gene Therapy for Critical Limb Ischemia and Peripheral Arterial Disease - Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Disease and Central Nervous System Disorders - ixmyelocel-T - JVS-100 - MultiGeneAngio - MultiStem - PLX-PAD - Protein for Myocardial Infarction and Critical Limb Ischemia - Recombinant Protein for Critical Limb Ischemia - Refacell-CLI - ReN-009 - Stem Cell Therapy for Critical Limb Ischemia - Stem Cell Therapy for Critical Limb Ischemia - Stem Cell Therapy to Activate VEGF for Critical Limb Ischemia - Stempeucel - Stromal Cell Therapy for Critical Limb Ischemia - TM-700 - VM-202 For more information visit http://www.researchandmarkets.com/research/sc...tical_limb
VCEL: 2.35 (+0.07), PSTI: 1.51 (unch), NBS: 2.25 (-0.09), ATHX: 2.14 (+0.05)
Leading 100 Global Fastest Growing Medical Devices/Technology/Supplies Companies 2015
M2 - Tue Mar 24, 7:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7ncq7z/global_fastest) has announced the addition of the "Global Fastest Growing Medical Devices/Technology/Supplies 100 - An Industry Report" report to their offering. The outlook for the medical device industry seems bright, with sales expected to still increase despite global economies struggling. The medical device market growth rate is expected to accelerate to 4.4% annually and reach $440 billion by 2018. This newly launched report identifies 100 Fastest Growing medical devices/technology/supplies companies globally and covers various aspects of these 100 companies including news, financial/non-financial information and stock market analysis. That is a growth rate almost 33% faster than the prescription drug market, which is expected to grow at a rate of 2.5% annually. The medical device market includes everything from large imaging systems to tongue depressors. While the pharmaceutical market represents a larger amount of dollars, the device market is responsible for more orders and transactions. The medical devices market is a major contributor to the overall healthcare industry with the pharmaceuticals industry leading the healthcare sector. The rising incidence of various diseases in the areas of Cardiovascular devices (CVD), respiratory, oncology, neurology, and many others have expanded the need for faster and better medical devices for treatment and diagnosis. The study of global top 100, by various attributes, in the medical devices market is important mainly due to continuous technological advancements in the medical devices industry and rising demand for medical devices owing to increasing healthcare issues. Report Highlights: - Global Fastest Growing 100 medical devices/technology/supplies companies - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of Global Fastest Growing medical devices/technology/supplies companies with foreign companies - International presence of Global Fastest Growing medical devices/technology/supplies companies - Key R&D activities by Global Fastest Growing medical devices/technology/supplies companies Companies Mentioned (Partial List) - Aethlon Medical Inc. (United States) - Anteo Diagnostics Limited (Australia) - Artventive Medical Group, Inc (United States) - Biodrain Medical Inc (United States) - Cardiovascular Systems, Incorporation (United States) - Electrical Geodesics, Inc. (United States) - GI Dynamics, Inc. (United States) - Inovio Pharmaceuticals Inc (United States) - Neurosynaptic Communications Pvt. Ltd (India) - Oncosil Medical Ltd (Australia) - ReNeuron Group plc (United Kingdom) - Rewalk Robotics Ltd (United States) - Scivision Biotech Inc (Taiwan) - SPO Global Inc (United States) - Suda Ltd (Australia) - West Pharmaceutical Packaging India Pvt Ltd (India) - Windmill Health Technologies Private Limited (India) - Xtremum Solutions Private Limited (India) For more information visit http://www.researchandmarkets.com/research/7n...al_fastest
INO: 9.85 (+0.21), CSII: 21.33 (+0.10), AEMD: 6.30 (-0.04)
